Strides Arcolab’s arm gets US FDA nod for Paclitaxle injection

30 Sep 2011 Evaluate

Onco Therapies, a division of Agila, which is a wholly owned subsidiary of Strides Arcolab, has received US Food and Drug Administration (FDA) approval for Paclitaxle injection USP, 6mg/ml packaged in 30mg/ml, 100mg/ml and 300mg/ml multiple dose vials.

Paclitaxle injection is among the products in the drug shortage list of the America Society of Health-System Pharmacists and the USFDA. The US market of Paclitaxle is about $46 million. The company will launch the product immediately.

The company has also got tentative approval for Oxaliplatin injection which has a US market of about $1.4 billion.

Recently, Onco Therapies received European Union (EU) approval for Oxaliplantin Injection 5mg/ml (10ml, 20ml and 40ml). This is the second European approval out of the 22 filings made by OTL in the year 2010 for products which have a combined market value of over $5 billion.

Strides Arcolab is global pharmaceuticals company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceuticals products with emphasis on sterlite injectables.

Strides Pharma Scien Share Price

671.25 34.80 (5.47%)
05-May-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1835.15
Dr. Reddys Lab 1172.50
Cipla 1543.10
Lupin 2087.30
Zydus Lifesciences 892.15
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
×
Please wait your portfolio is updating...